Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sofie Ellebaek Pollmann"'
Autor:
Thomas Tuxen Poulsen, Michael Kragh, Emanuel F. Petricoin, Andreas Kjaer, Ivan D. Horak, Subha Madhavan, Simina M. Boca, Shruti Rao, Valerie S. Calvert, Sofie Ellebaek Pollmann
Supplementary Figure S1. Sequence homology to human and mouse reference genomes. Supplementary Figure S2. No SNU-5 tumors establish upon continuous treatment with emibetuzumab Supplementary Figure S3. MET level in 7333 and with or without emibetuzuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b9bd18910807e7e3fd33a90ecdfd809
https://doi.org/10.1158/1535-7163.22505647.v1
https://doi.org/10.1158/1535-7163.22505647.v1
Autor:
Thomas Tuxen Poulsen, Michael Kragh, Emanuel F. Petricoin, Andreas Kjaer, Ivan D. Horak, Subha Madhavan, Simina M. Boca, Shruti Rao, Valerie S. Calvert, Sofie Ellebaek Pollmann
Supplementary Table S4. Sensitivity of emibetuzumab-resistant cell lines to various TKIs compared with SNU-5 cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b519fa2fdfe0d66a05a6aea38c1df4e2
https://doi.org/10.1158/1535-7163.22505635.v1
https://doi.org/10.1158/1535-7163.22505635.v1
Autor:
Thomas Tuxen Poulsen, Michael Kragh, Emanuel F. Petricoin, Andreas Kjaer, Ivan D. Horak, Subha Madhavan, Simina M. Boca, Shruti Rao, Valerie S. Calvert, Sofie Ellebaek Pollmann
Supplementary Table S3. Limma output from comparison of 4626 with parental SNU-5 cells treated with emibetuzumab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01cbd787d3ce5a70adeb6d2fcb896580
https://doi.org/10.1158/1535-7163.22505638.v1
https://doi.org/10.1158/1535-7163.22505638.v1
Autor:
Thomas Tuxen Poulsen, Michael Kragh, Emanuel F. Petricoin, Andreas Kjaer, Ivan D. Horak, Subha Madhavan, Simina M. Boca, Shruti Rao, Valerie S. Calvert, Sofie Ellebaek Pollmann
Supplementary Table S1. Total list of detection antibodies used for reverse phase protein array.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb8f00865ed78cfadb4430058eb2e91
https://doi.org/10.1158/1535-7163.22505644.v1
https://doi.org/10.1158/1535-7163.22505644.v1
Autor:
Thomas Tuxen Poulsen, Michael Kragh, Emanuel F. Petricoin, Andreas Kjaer, Ivan D. Horak, Subha Madhavan, Simina M. Boca, Shruti Rao, Valerie S. Calvert, Sofie Ellebaek Pollmann
Supplementary Table S2. Limma output from comparison of 7333 with parental SNU-5 cells treated with emibetuzumab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::871e17a65ba62ddcf93d6f5901f85f40
https://doi.org/10.1158/1535-7163.22505641.v1
https://doi.org/10.1158/1535-7163.22505641.v1
Autor:
Thomas Tuxen Poulsen, Michael Kragh, Emanuel F. Petricoin, Andreas Kjaer, Ivan D. Horak, Subha Madhavan, Simina M. Boca, Shruti Rao, Valerie S. Calvert, Sofie Ellebaek Pollmann
Failure of clinical trials due to development of resistance to MET-targeting therapeutic agents is an emerging problem. Mechanisms of acquired resistance to MET tyrosine kinase inhibitors are well described, whereas characterization of mechanisms of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eda0981f2b53e565934ad1a6bbd745d
https://doi.org/10.1158/1535-7163.c.6538138.v1
https://doi.org/10.1158/1535-7163.c.6538138.v1
Autor:
Thomas Tuxen Poulsen, Michael Kragh, Emanuel F. Petricoin, Andreas Kjaer, Ivan D. Horak, Subha Madhavan, Simina M. Boca, Shruti Rao, Valerie S. Calvert, Sofie Ellebaek Pollmann
Supplementary Table S5. Detection of HGF in cell supernatants.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8aca5ac4e087589e3b86a8d143badaa3
https://doi.org/10.1158/1535-7163.22505632.v1
https://doi.org/10.1158/1535-7163.22505632.v1
Autor:
Michael Kragh, Johan Lantto, Ivan David Horak, Mikkel Wandahl Pedersen, Thomas Bouquin, Helle Jane Jacobsen, Anna Dahlman, Karsten Wessel Eriksen, Sofie Ellebæk Pollmann, Camilla Fröhlich, Trine Lindsted, Klaus Koefoed, Lene Alifrangis, Rikke Hald, Niels Jørgen Østergaard Skartved, Michael Monrad Grandal, Thomas Tuxen Poulsen
Purpose: Activation of the receptor tyrosine kinase MET is associated with poor clinical outcome in certain cancers. To target MET more effectively, we developed an antagonistic antibody mixture, Sym015, consisting of two humanized mAbs directed agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd42e8fa5152a6352745a4a5a20e3a4
https://doi.org/10.1158/1078-0432.c.6526412
https://doi.org/10.1158/1078-0432.c.6526412
Autor:
Michael Kragh, Johan Lantto, Ivan David Horak, Mikkel Wandahl Pedersen, Thomas Bouquin, Helle Jane Jacobsen, Anna Dahlman, Karsten Wessel Eriksen, Sofie Ellebæk Pollmann, Camilla Fröhlich, Trine Lindsted, Klaus Koefoed, Lene Alifrangis, Rikke Hald, Niels Jørgen Østergaard Skartved, Michael Monrad Grandal, Thomas Tuxen Poulsen
Supplementary Materials and Methods and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca4d336b8f571c5de061618b189a3dd
https://doi.org/10.1158/1078-0432.22466729.v1
https://doi.org/10.1158/1078-0432.22466729.v1
Autor:
Michael Kragh, Johan Lantto, Ivan David Horak, Mikkel Wandahl Pedersen, Thomas Bouquin, Helle Jane Jacobsen, Anna Dahlman, Karsten Wessel Eriksen, Sofie Ellebæk Pollmann, Camilla Fröhlich, Trine Lindsted, Klaus Koefoed, Lene Alifrangis, Rikke Hald, Niels Jørgen Østergaard Skartved, Michael Monrad Grandal, Thomas Tuxen Poulsen
Suppl. Figure 1 In vivo efficacy of Sym015 treatment at various dose levels in the EBC-1 xenograft model. Suppl. Figure 2 In vivo efficacy of Sym015 and unbalanced mixtures of the two constituent antibodies Hu9006 and Hu9338, applied at 10 mg/kg or 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9841d7b6cf28b9cccd9876803b7652
https://doi.org/10.1158/1078-0432.22466732.v1
https://doi.org/10.1158/1078-0432.22466732.v1